Biographical details

Mohamed A Alhnan joined KCL as a Senior Lecturer in Pharmaceutical Medicine in the School of Cancer & Pharmaceutical Sciences in Sep 2018, and was promoted to Reader in 2023. Mohamed has been a registered pharmacist in the UK since 2011. He worked on site-specific oral drug delivery for this PhD project in London School of Pharmacy (now UCL School of Pharmacy). After working on several industrial projects, he worked as lecturer then as a senior lecturer in the School of Pharmacy and Biomedical Sciences in University of Central Lancashire.

Research interests

Mohamed’s research focuses on applying the latest advances in material science and electronics in the pharmaceutical field. This research is an endeavour to bridge the gap between drug delivery and pharmaceutical technology on one hand and new design and production methods such as 3D printing on the other hand. The goal of this effort is to break current boundaries of oral drug delivery systems and formulation design and to link pharmacy to an increasingly smart and digitally connected environment of this age. This effort can enable the digitalisation of dosage form design and prototyping, innovation of new drug delivery systems that are responsive to biosensors and environmental changes as well as improving the personalisation of dosage forms. His fundamental research has led to several world firsts; first example of using pharmaceutical grade polymers in FDM 3D printing, first 3D printed tablets to meet the US and British Pharmacopoeias for delayed release products, and first examples of 3D printing of liquid capsule. He introduced and patented the innovative concept of tablets of complex architecture as a solution for fast disintegration and dissolution. Mohamed is working with industrial and clinical partners on the manufacturing of 3D printed dosage forms. He is also collaborating with two global manufacturers of pharmaceutical coating on the scale-up and commercialising a next generation of coating solution of nutraceutical products.